A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

Summary

This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.

Timeline

Start

2022-05-10

Primary completion

2026-06-30

Completion

2027-09-30

Drugs

Indications